SOSV

InnSight Technology is a biotechnology company focused on advancing the diagnostics and evaluation of eye diseases. The company specializes in developing innovative ophthalmic devices, including a novel, hand-held biosensor designed for the detection of anterior ophthalmic injuries. Additionally, InnSight Technology works on the development of nanotechnology-based medical devices aimed at addressing various clinical needs in ophthalmology. By providing these advanced tools, the company enables clinicians to enhance ocular care and improve patient outcomes in eye health.

Sharper Sense is a company that specializes in wearable neurotechnology designed to enhance sensory acuity, specifically vision, hearing, and touch. The firm has developed a neuromodulation patch that utilizes noninvasive electrical stimulation to improve sensory processing. This innovative technology has both clinical and commercial applications, including the treatment of sensory processing disorders and sensory loss. By providing users with clearer and more accurate perceptions, Sharper Sense aims to enhance performance and safety in various environments, ultimately improving the overall sensory experience.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Ostoform Limited is a medical device company based in Dublin, Ireland, specializing in products designed to manage skin complications for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform has developed patented technologies aimed at enhancing ostomy skin health. Its flagship products include a mouldable seal that fits securely around the stoma, preventing corrosive output from contacting the skin, and FLOWASSIST, which directs stoma output away from the skin to minimize irritation and swelling. By addressing these significant challenges faced by ostomy patients, Ostoform aims to improve comfort and overall quality of life, positioning itself as a potential leader in the global ostomy care market.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Proton Intelligence, founded in 2020 and headquartered in Vancouver, Canada, specializes in biomarker monitoring to manage chronic diseases and enhance patient outcomes. The company focuses on continuous potassium monitoring, particularly for patients suffering from hyperkalemia associated with chronic kidney disease and other co-morbidities. Proton Intelligence's innovative platform provides accurate and real-time potassium measurements through interstitial fluid analysis, which correlates closely with blood levels. This capability is critical for enabling timely and informed decision-making regarding patient care, allowing clinicians and patients to effectively manage medications, dietary choices, and treatment options. By prioritizing precise monitoring, Proton Intelligence aims to significantly improve the health and lives of individuals affected by hyperkalemia.

Serene Sleep is a medical technology company that focuses on improving sleep quality by addressing snoring and sleep apnea. It develops and offers a non-invasive, targeted treatment procedure using palatal implants, designed to reduce disruptive snoring and enhance overall sleep for both the individual and their partner.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

Machine Medicine Technologies Ltd, established in 2017 and based in London, UK, specializes in developing artificial intelligence-driven solutions for healthcare. The company's core product, KELVIN-PD, employs computer vision and pose estimation to objectively measure and analyze movement disorders, such as tremors and bradykinesia, in Parkinson's disease patients using simple video clips. This platform offers secure data management, accessibility from various devices, and affordability, making it a valuable tool for researchers and clinicians.

Exosomm is an innovative foodtech start-up focused on developing nutritional solutions derived from natural milk exosomes. The company was founded based on research from Hadassah Medical Center, led by Prof. Reif's team. Exosomm's flagship product is a specialized food formula designed for patients suffering from inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. This product utilizes a patented active anti-inflammatory ingredient sourced from milk exosomes, which are isolated using a natural and environmentally friendly process. By targeting health and immunity, Exosomm aims to provide effective solutions for individuals with specific dietary needs.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Metabolic Psychiatry Labs is a mental healthcare company that provides remote treatment solutions for mental illnesses. Their platform integrates metabolic and mental health research, data tracking, metabolic interventions, and personalized medical care, enabling patients to receive effective treatments from home. The company offers assessments, lab tests, and wellness solutions based on metabolic therapy.

Minutia is a biotechnology company focused on developing innovative stem cell-derived transplants aimed at treating Type 1 Diabetes. The company specializes in creating insulin-producing cell transplants that incorporate proprietary nanosensors, allowing for real-time monitoring of transplant status. These immune-evasive cells are designed for subcutaneous implantation, addressing common challenges associated with transplant procedures. By advancing this technology, Minutia seeks to transform the clinical landscape for diabetes management and cell replacement therapies, ultimately working towards a functional cure for this condition.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calyx specializes in developing advanced sensor technology focused on monitoring environmental parameters, particularly in the poultry and livestock sectors. The company integrates artificial intelligence, computer vision, and bio-engineered sensors to create versatile platforms capable of detecting airborne chemical emissions with high specificity and sensitivity. Its innovative sensors are designed using patterned viruses that bind to specific gas molecules, allowing for accurate detection of various airborne chemicals. This technology not only addresses complex challenges in livestock management but also enables commercial customers to monitor and respond to daily environmental health changes effectively.

Bloomlife is a pioneering women's health company focused on enhancing maternal care through innovative technology. By integrating connected devices with cloud-based data analytics, Bloomlife aims to improve access to care for expectant mothers and empower them with crucial information. The company's remote maternal care platform facilitates the monitoring of high-risk pregnancies, allowing obstetricians to better assess maternal and fetal risks and educate patients effectively. Bloomlife’s solutions reduce the need for frequent in-person appointments and lengthy referral processes, thus streamlining the management of pregnancy complications. With a commitment to redefining maternal health, Bloomlife seeks to become the leading provider of remote care for expectant women worldwide, ultimately improving health outcomes for mothers and babies.

Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative, off-the-shelf cell therapies for treating cancer and autoimmune diseases. The company focuses on creating allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies, which use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions. This approach aims to increase treatment accessibility and scalability by utilizing non-patient-specific cells.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Zhenshi Medical is a medical device company that specializes in lung puncture medical robots for diagnosing and treating lung cancer.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in the development of an innovative artificial intelligence-powered magnetic resonance imaging (MRI) system. The company's technology aims to significantly reduce the cost, size, and weight of traditional MRI machines, thereby enhancing accessibility to medical imaging for patients worldwide. By utilizing generative topological design for its hardware and deep learning techniques for image processing, DeepSpin's MRI system seeks to make advanced medical imaging available in a variety of previously underserved healthcare settings. This approach not only aims to improve patient care but also to democratize access to essential medical diagnostics globally.

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Kegg is a company that specializes in women's health, focusing on fertility tracking and pelvic floor exercising. Established in 2017 and based in San Francisco, California, Kegg has developed an innovative device that combines these two aspects into a single, user-friendly product. The device effectively tracks changes in vaginal and cervical fluids, enabling users to identify their fertile window and predict ovulation up to seven days in advance. This capability significantly enhances the chances of natural conception by providing women with crucial data to support informed decisions regarding their reproductive health. By implementing advanced sensing technology, Kegg aims to improve diagnosis, monitoring, and treatment related to women's fertility.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

OncoPrecision is a biotechnology company focused on enhancing cancer treatment through its innovative patient micro avatar platform. This platform utilizes single-cell high-throughput biology and advanced machine learning techniques to develop comprehensive patient-derived phenotypic biomarkers. By tailoring cancer therapies to individual patients, OncoPrecision aims to significantly increase the success rates of treatments. The company's approach enables oncologists to make informed, data-driven decisions regarding therapy selection based on unique patient samples, thereby improving outcomes in cancer care.

GlowDx, established in 2015 and headquartered in Midleton, Ireland, specializes in developing point-of-care diagnostic solutions. The company aims to decentralize molecular testing, enabling local access to improve clinical outcomes and reduce economic burden for patients, particularly in tropical disease diagnosis. GlowDx achieves this by employing novel molecular technology tailored for efficient, on-site diagnostics.

FeetMe is a digital health company that specializes in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative footwear products equipped with connected insoles that analyze patients' mobility and posture in real time. By integrating pressure sensors and motion algorithms, FeetMe's technology provides valuable insights into gait patterns and movement disorders. This enables healthcare professionals to enhance patient care, monitor disease progression, and optimize treatment plans. FeetMe's focus on delivering relevant digital biomarkers supports clinical research and aims to improve the quality of life for individuals facing mobility challenges.

VisusNano Ltd. is a London-based company founded in 2016 that specializes in the development of a drug-eluting intraocular lens implant designed for use in cataract surgery. This innovative technology aims to enhance patient outcomes by reducing the risks associated with the procedure, such as intraocular inflammation, infection, and opacification. By eliminating the need for postoperative eye drops and minimizing the necessity for laser treatments, VisusNano's product has the potential to transform cataract surgery for both human and veterinary patients. The company is currently in the pre-clinical stage of its development.

Lief Therapeutics is a medical device company based in San Francisco, California, focused on enhancing at-home care for individuals dealing with post-traumatic stress disorder, depression, and anxiety. The company has developed a discreet bio-sensing patch that accurately measures heart rate and breath, allowing users to manage their natural stress response through vibratory biofeedback exercises. This wearable device helps users monitor their behaviors, emotions, and thoughts in real-time, fostering mindfulness and control throughout the day. Additionally, it supports clinicians by tracking patient progress, facilitating in-session training, and scheduling psychological assessments. Lief Therapeutics also offers the Lief Health Score application, which records thoughts, emotions, and sensations, enabling users to track daily progress and engage in tailored exercises. Founded in 2014, the company sells its products online, aiming to empower individuals in their mental health journeys.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Level Zero Health is a technology company specializing in advanced biosensor solutions. It develops wearable devices equipped with DNA-based sensors, designed to precisely monitor key endocrine biomarkers in real-time. By combining biochemistry and nanotechnology, the company collects novel data, empowering users to gain insights into their hormonal health.

Strados Labs, LLC is a medical technology company based in Philadelphia, Pennsylvania, specializing in respiratory health management through innovative sensor-based solutions. Founded in 2016, the company has developed a wearable device that provides real-time insights into breathing patterns, sounds, and speed. This device is equipped with clinical-grade biosensors and smart software, allowing for continuous monitoring of respiratory conditions such as asthma and chronic obstructive pulmonary disease. By connecting to a mobile application, Strados enables users and healthcare providers to access and analyze respiratory data, facilitating informed health decisions and remote patient monitoring.

Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Feel Therapeutics is a digital precision medicine company focused on mental health. It develops physiological and digital biomarkers, along with therapeutics, to enhance the diagnosis, management, and care of mental health conditions. The company's flagship product is a data monitoring device, which is a wristband equipped with five embedded sensors that collect biometric data. This data is analyzed using advanced computer science techniques to create digital biomarkers. Feel Therapeutics aims to provide objective data and passive monitoring to help users improve their mental well-being and cultivate lasting positive emotional habits through its proprietary algorithms and medical-grade wearables.

Chronus Health, Inc. is a medical technology company that specializes in developing a portable diagnostic device capable of delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in Mountain View, California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time diagnostic capabilities. This innovative system allows for the delivery of lab results within minutes, significantly enhancing the speed of diagnosis and improving patient outcomes by enabling timely and informed treatment decisions.

Verdex Technologies is a company based in Chesterfield, Virginia, specializing in the design, patenting, and licensing of non-toxic nanofiber producing equipment for filtration and biomedical applications. Founded in 2011, Verdex focuses on mass-producing high-quality nanofibers using proprietary green technology, which avoids toxic solvents or petroleum products. The company's innovative process allows nano-fibers to be functionalized by impregnating them with other nano-sized ingredients, enhancing the effectiveness of various products such as water filters and face masks. Verdex's scalable technology platform enables the cost-effective production of nanofiber materials from a wide range of natural and synthetic polymers, making it commercially feasible for numerous applications including engine filters, liquid filters, industrial air filters, and technical textiles.

Lura Health is a pioneering company that has developed a non-invasive continuous health monitoring platform utilizing saliva as a diagnostic fluid. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company focuses on chronic disease management, targeting conditions such as heart disease, chronic kidney disease, diabetes, and tooth decay. Lura Health's innovative sensors are designed to be integrated into patient-friendly orthodontic devices, including removable retainers and fixed brackets. These sensors continuously monitor oral acidity and other analytes in saliva, automatically transmitting valuable health data to a mobile application. This approach empowers users to track key diagnostic metrics within their oral environment, facilitating improved personal health management and potentially enhancing clinical outcomes.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Hypercell Technologies specializes in developing innovative tools for controlling infectious diseases in animals. The company's core focus is on creating rapid, accurate diagnostic tools using molecular biology techniques, which enable veterinarians to detect and manage infections swiftly. Additionally, Hypercell develops monoclonal antibodies designed to proactively control viruses in production animal reservoirs, aiming to prevent potential zoonotic disease outbreaks in humans by addressing the source in animals.

FluidAI Medical is a medical platform company focused on enhancing global patient care through the innovative application of artificial intelligence in post-operative recovery. The company has developed a smart catheter system that fosters a proactive approach to post-operative care delivery. By utilizing data generated within the body, FluidAI's platform aids in the early detection of postoperative complications, allowing healthcare providers to access critical health information promptly. This technology aims to improve patient outcomes and streamline the management of post-operative recovery processes.

Optimize Health is a provider of a digital healthcare platform focused on enabling Remote Patient Monitoring (RPM) programs. The company offers user-friendly equipment and software designed to support healthcare providers in managing patient care efficiently. Its platform automatically tracks medication doses and sends reminders to patients, ensuring adherence to treatment plans by syncing with smartphones or tablets. This system not only enhances patient engagement but also assists providers in complying with billing requirements for new Medicare codes, promoting profitability for physicians from the outset. Through its innovative approach, Optimize Health aims to improve health outcomes and streamline the management of chronic conditions.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Medical Devices, Kidney Disease, Wearables, Medtech, Hardtech

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

LightHearted AI is a company that specializes in developing an AI-driven remote cardiovascular diagnostics tool aimed at improving the detection of heart conditions. This medical device is designed to deliver rapid, precise, and cost-effective assessments, addressing the critical need to prevent heart-related deaths. By leveraging advanced technology, LightHearted AI enhances the capabilities of healthcare professionals, allowing for faster and more accurate diagnostic procedures compared to traditional methods. The company's innovation seeks to transform cardiac care, ultimately contributing to better treatment outcomes for patients.

Xias Bio is a biotechnology startup focused on the development and production of recombinant proteins. The company specializes in creating non-immunogenic natural motifs that enhance the delivery of functionalities for various applications in research, beauty, and healthcare. Xias Bio's innovative platform provides a versatile, animal product-free biomaterial that offers tailored biological functionality. This approach enables pharmaceutical and cosmetic companies to access designer proteins that serve as non-immunogenic, non-toxic alternatives to traditional synthetic and animal-derived materials. By improving attributes such as gel and film formation, as well as antioxidant properties, Xias Bio addresses the limitations of conventional solutions, positioning itself as a valuable partner in the biotechnology sector.

MedIQ is an integrated virtual care platform providing on-demand healthcare at the point of need. MedIQ redefines healthcare through a digitally enabled, cashless, hybrid healthcare ecosystem. MedIQ makes high-quality, modernized healthcare and wellness available to everyone.

QuantumCyte, Inc. is a technology platform company focused on advancing cancer treatment and drug efficacy prediction through innovative cell analysis systems. Established in 2014 and headquartered in Sunnyvale, California, QuantumCyte develops automated microdissection solutions that utilize digital tissue maps to pinpoint regions of interest containing critical biomarkers for treatment decisions. By leveraging artificial intelligence in its digital pathology and molecular analysis technologies, the company provides healthcare providers with precise cellular data, enabling in-depth single-cell analysis that enhances understanding of immune system and cancer biology. Through its efforts, QuantumCyte aims to improve cancer outcomes and contribute to more effective therapeutic interventions.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Lios, founded in 2009 by Rhona Togher and Eimear O’Carroll, is dedicated to combating noise pollution through innovative materials and technologies. Originally known as Restored Hearing, the company focuses on reducing the risk of exposure to loud noise and mitigating its effects. Lios integrates advanced knowledge in physics with expertise in hearing damage to develop solutions that address industry challenges. One of their flagship products, SoundBounce, is a revolutionary acoustic material designed for use in automotive, aerospace, construction, and power generation industries, offering superior noise reduction while being significantly thinner than traditional solutions. Additionally, Lios provides SoundRelief, a tinnitus sound therapy app available on mobile devices, which is designed to improve the quality of life for users experiencing ringing in the ears. This app has been scientifically validated and is CE mark approved, making it accessible to individuals in over 60 countries. Through its innovative approach, Lios aims to foster a quieter world by providing effective noise dampening solutions.

Feel Therapeutics is a digital precision medicine company focused on mental health. It develops physiological and digital biomarkers, along with therapeutics, to enhance the diagnosis, management, and care of mental health conditions. The company's flagship product is a data monitoring device, which is a wristband equipped with five embedded sensors that collect biometric data. This data is analyzed using advanced computer science techniques to create digital biomarkers. Feel Therapeutics aims to provide objective data and passive monitoring to help users improve their mental well-being and cultivate lasting positive emotional habits through its proprietary algorithms and medical-grade wearables.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Verdex Technologies is a company based in Chesterfield, Virginia, specializing in the design, patenting, and licensing of non-toxic nanofiber producing equipment for filtration and biomedical applications. Founded in 2011, Verdex focuses on mass-producing high-quality nanofibers using proprietary green technology, which avoids toxic solvents or petroleum products. The company's innovative process allows nano-fibers to be functionalized by impregnating them with other nano-sized ingredients, enhancing the effectiveness of various products such as water filters and face masks. Verdex's scalable technology platform enables the cost-effective production of nanofiber materials from a wide range of natural and synthetic polymers, making it commercially feasible for numerous applications including engine filters, liquid filters, industrial air filters, and technical textiles.

TippingPoint Biosciences is focused on developing innovative therapeutics that address diseases caused by defects in DNA packaging, with an emphasis on conditions such as cancer and neurodegenerative disorders. Utilizing a specialized drug discovery platform, the company aims to identify new treatment options that specifically target unique genome packaging states associated with various diseases. This approach not only facilitates the treatment of cancer but also holds potential for advancing stem cell therapies by correcting dysfunctional genome packaging. Through its research and development efforts, TippingPoint Biosciences seeks to provide effective solutions for complex medical challenges.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

Samphire Neuroscience, founded in 2021 and based in London, specializes in women's health through innovative neurotechnology solutions. The company develops a headband device that utilizes non-invasive electrical neuromodulation to target specific areas of the brain. This approach aims to alleviate symptoms commonly associated with the menstrual cycle, such as pain, fatigue, and mood fluctuations. By focusing on enhancing women's health and lifestyles, Samphire Neuroscience strives to provide effective relief for those affected by these challenges.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative therapies for cancer treatment. The company specializes in creating Pannexin 1 channel (Panx1) blockers, which represent a novel class of drugs aimed at inhibiting multiple pathways that contribute to the growth, spread, and survival of cancer cells. Pannex Therapeutics' therapies are designed to provide high specificity for cancer cells, ensuring effective treatment while minimizing side effects and the risk of addiction. By advancing these promising treatments, the company seeks to transform cancer therapy and improve patient outcomes.

Optimize Health is a provider of a digital healthcare platform focused on enabling Remote Patient Monitoring (RPM) programs. The company offers user-friendly equipment and software designed to support healthcare providers in managing patient care efficiently. Its platform automatically tracks medication doses and sends reminders to patients, ensuring adherence to treatment plans by syncing with smartphones or tablets. This system not only enhances patient engagement but also assists providers in complying with billing requirements for new Medicare codes, promoting profitability for physicians from the outset. Through its innovative approach, Optimize Health aims to improve health outcomes and streamline the management of chronic conditions.

Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its innovative platform enhances surgical capabilities by providing real-time, high-resolution imaging combined with 3D navigation features. This technology significantly improves surgeons' ability to visualize small objects in the human body, facilitating the early detection of conditions such as cancer. By advancing imaging techniques, Leadoptik aims to enhance surgical precision and improve patient outcomes.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

AvantGuard creats innovative solutions that manage surfaces and provide long-term protection against viruses, bacteria, and fungi/mold, in a variety of applications.

Kresko RNAtech is a biotechnology company focused on the development and production of nutraceuticals. It specializes in identifying bioactive ribonucleic acids (RNAs) from natural sources, utilizing advanced techniques such as machine learning and bioinformatics. By discovering RNAs that may offer health benefits, Kresko RNAtech aims to assist researchers in enhancing human well-being and addressing the challenges posed by stressful and changing environments through innovative RNA technologies.

Geltor, Inc. is a biodesign company focused on producing bioactive, animal-free collagens and proteins for a range of applications including beauty and nutrition. The company offers innovative products such as Collume, a bio-designed collagen technology that supports skincare cellular regeneration, and HumaColl21, which enhances the skin's appearance by boosting collagen, elastin, laminin, and fibronectin levels. Geltor also provides vegan collagen peptides and other novel proteins for use in functional foods and nutraceuticals. Established in 2015 and based in San Leandro, California, Geltor is committed to sustainable practices and aims to support a plant-based future through its clinically validated, biocompatible materials.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

AuraSense is a company that leverages artificial intelligence and automation to enhance neurological examinations, converting subjective assessments into quantifiable data. By merging video game technology with practical medical procedures, AuraSense develops digital touch technology that enables the early detection of limb damage and facilitates remote physical examinations for various diseases. This innovative approach allows neurologists to accurately evaluate patients' cognitive and physical health, leading to personalized treatment plans tailored to individual needs. Through its technology, AuraSense aims to improve health outcomes and ensure that patients receive effective, data-driven care.

Beeflow S.A., founded in 2016 and based in Buenos Aires, Argentina, specializes in professional pollination services that leverage scientific knowledge and technology to enhance bee health and efficiency. The company develops organic compounds that improve the immune systems of bees and train them to pollinate specific crops, such as blueberries, almonds, raspberries, and kiwifruit. By providing these specialized pollination services, Beeflow enables farmers to significantly increase crop yields, with reported improvements ranging from 20% to 90%, while simultaneously addressing the decline in bee populations. Through its innovative approach, Beeflow aims to support agricultural productivity and ecosystem sustainability.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Kolibri is a biotechnology company focused on revolutionizing large-scale cell culture to enhance accessibility and affordability in cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that employs advanced techniques in acoustics and biology, enabling its bioreactors to achieve a 90-fold increase in cell yield while significantly reducing production costs by up to 50 times. Kolibri's innovative bioreactors are designed to facilitate the efficient growth of cells at scale, thereby supporting partners in drug development and providing critical solutions for unlocking patient access to gene therapies and next-generation vaccines. Through its technological advancements, Kolibri aims to address key challenges in the bioproduction of biologics.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

Renegade.bio is a biotechnology startup focused on the development and deployment of high-throughput diagnostics aimed at detecting novel infectious diseases. The company specializes in creating innovative diagnostics and assays that support drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). By leveraging these capabilities, Renegade.bio enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, and large events.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Mimio Health is a nutraceutical company dedicated to the research and development of fasting mimetic supplements. The company has created a patent-pending formulation that utilizes a carefully chosen blend of bioactive human metabolites designed to mimic the body's natural response to fasting. This innovative approach aims to replicate the cellular health benefits associated with fasting, enabling users to experience anti-inflammatory and antioxidant effects that may help combat age-related chronic inflammation and cellular damage, without the need for actual fasting. Through its scientific research, Mimio Health seeks to enhance overall wellness and longevity.

Pear Bio is a biotechnology company based in Boston and London that specializes in AI-enabled precision medicine for the treatment of challenging cancers. The company utilizes tumor biopsies and blood samples from cancer patients to identify new therapeutic targets through multi-omics analysis. Pear Bio's proprietary immune-microtumor platform allows for the testing of drug candidates directly on patient tumor samples, enhancing the efficacy of treatments. Additionally, the company employs a unique hydrogel technology that cultivates tumors outside the body, enabling the measurement of drug resistance and streamlining the treatment process. By focusing on tailored drug discovery and smarter combination therapies, Pear Bio aims to improve patient outcomes in cancer care.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.

Japet Medical Devices is a French biomedical company focused on developing advanced robotic equipment aimed at enhancing the quality of healthcare. The company specializes in wearable robotic exoskeletons that integrate medical and robotic technologies to improve motion and restore balance, thereby facilitating free movement and reducing pain. Their innovative solutions are designed to assist individuals in overcoming mobility challenges, whether related to occupational tasks or daily activities. By prioritizing efficiency and user-friendliness, Japet Medical Devices aims to transform the quality of life for many people through its cutting-edge technologies.